Survival of melanoma patients treated with novel drugs: retrospective analysis of real-world data
- 12 June 2017
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 143 (10) , 2087-2094
Abstract
Purpose Recently, several new drugs have been licensed for advanced melanoma therapy, significantly changing the therapeutic landscape. Ipilimumab and vemurafenib were the first drugs that demonstrated a survival benefit over the long-standing standard therapy with dacarbazine. However, the comparative efficacy of these novel drugs has not been properly assessed yet. Patients and methods We conducted a retrospective analysis of all the Polish population treated between January 2012 and October 2016 with one of the following agents: ipilimumab (IPI), vemurafenib (VEM), dabrafenib (DAB), and classic chemotherapy (CTH). The main objective was to assess the overall survival of melanoma patients treated in real-world conditions, taking into account sequences of treatment. Results We identified 3397 patients with malignant melanoma treated for the first line and the second line. Patients receiving CTH were significantly older than those treated with the novel drugs. At the same time, the population treated with immunotherapy and targeted therapy was well balanced. Overall survival was significantly better for the novel drugs compared to classic chemotherapy in both lines (for the first line, VEM vs CTH HR = 0.72, 95% CI 0.65–0.81; p < .01, and for the second line, VEM vs CTH HR = 0.78, 95% CI 0.62–0.98; p = .03; IPI vs CTH HR = 0.72, 95% CI 0.62–0.86; p < .01). There was no statistically significant difference for IPI vs VEM; however, subgroup analysis revealed superior results in the case of the CTH–IPI over BRAFi–IPI sequence. Conclusion Novel drugs for melanoma provide a significant advantage in survival over classic chemotherapy. Comparative assessment of IPI and VEM indicated no difference, but only immunotherapy-treated patients achieved long-lasting results. Our data on sequential treatment indicate that immunotherapy might be a better option for the first line rather than targeted therapy, but that conclusion requires further studies of the best way to manage the treatment of melanoma patients.Keywords
This publication has 23 references indexed in Scilit:
- Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety studyThe Lancet Oncology, 2014
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyThe Lancet Oncology, 2014
- Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitorsCancer, 2014
- Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastasesJournal of Neuro-Oncology, 2014
- Vemurafenib in the French temporary authorization for use metastatic melanoma cohortMelanoma Research, 2014
- Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access ProgramCancer Investigation, 2014
- Age is an independent poor prognostic factor in cutaneous head and neck melanomaThe Laryngoscope, 2013
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialThe Lancet, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010